en
Scientific article
Open access
English

Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity

Published inScientific Reports, vol. 7, 43005
Publication date2017
Abstract

Ruthenium-based compounds show strong potential as anti-cancer drugs and are being investigated as alternatives to other well-established metal-based chemotherapeutics. The organometallic compound [Ru(η6-p-cymene)Cl2(pta)], where pta = 1,3,5-triaza-7-phosphaadamantane (RAPTA-C) exhibits broad acting anti-tumor efficacy with intrinsic angiostatic activity. In the search for an optimal anti-angiogenesis drug combination, we identified synergistic potential between RAPTA-C and the epidermal growth factor receptor (EGFR) inhibitor, erlotinib. This drug combination results in strong synergistic inhibition of cell viability in human endothelial (ECRF24 and HUVEC) and human ovarian carcinoma (A2780 and A2780cisR) cells. Additionally, erlotinib significantly enhances the cellular uptake of RAPTA-C relative to treatment with RAPTA-C alone in human ovarian carcinoma cells, but not endothelial cells. Drug combinations induce the formation of chromosome bridges that persist after mitotic exit and delay abscission in A2780 and A2780cisR, therefore suggesting initiation of cellular senescence. The therapeutic potential of these compounds and their combination is further validated in vivo on A2780 tumors grown on the chicken chorioallantoic membrane (CAM) model, and in a preclinical model in nude mice. Immunohistochemical analysis confirms effective anti-angiogenic and anti-proliferative activity in vivo, based on a significant reduction of microvascular density and a decrease in proliferating cells.

Keywords
  • Animals
  • Antineoplastic Agents/chemistry/pharmacology/therapeutic use
  • Cell Line
  • Tumor
  • Cell Movement/drug effects
  • Cell Survival/drug effects
  • Cellular Senescence/drug effects
  • Chickens
  • Chorioallantoic Membrane/drug effects/physiology
  • Cymenes
  • Drug Resistance
  • Neoplasm/drug effects
  • Drug Synergism
  • Drug Therapy
  • Combination
  • Erlotinib Hydrochloride/chemistry/pharmacology/therapeutic use
  • Female
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Mice
  • Mice
  • Nude
  • Neovascularization
  • Physiologic/drug effects
  • Organometallic Compounds/chemistry/pharmacology/therapeutic use
  • Ovarian Neoplasms/drug therapy/pathology
Citation (ISO format)
BERNDSEN, Robert H et al. Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. In: Scientific Reports, 2017, vol. 7, p. 43005. doi: 10.1038/srep43005
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal2045-2322
233views
141downloads

Technical informations

Creation06/25/2020 2:54:00 PM
First validation06/25/2020 2:54:00 PM
Update time03/15/2023 10:12:39 PM
Status update03/15/2023 10:12:38 PM
Last indexation05/05/2024 4:57:11 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack